Abstract:Antimicrobial drug resistance poses a global health threat, requiring a deeper understanding of the evolutionary processes that lead to its emergence in pathogens. Complex evolutionary dynamics involve multiple mutations that can result in cooperative or competitive (clonal interference) effects. Candida albicans , a major fungal pathogen, displays high rates of copy number variation (CNV) and loss of heterozygosity (LOH). CNV and LOH events involve large numbers of genes and could synergize during evolutionary adaptation. Understanding the contributions of CNV and LOH to antifungal drug adaptation is challenging, especially in the context of whole-population genome sequencing. Here, we document the sequential evolution of fluconazole tolerance and then resistance in a C . albicans isolate involving an initial CNV on chromosome 4, followed by an LOH on chromosome R that involves KSR1 . Similar LOH events involving KSR1 , which encodes a reductase in the sphingolipid biosynthesis pathway, were also detected in independently evolved fluconazole resistant isolates. We dissect the specific KSR1 codons that affect fluconazole resistance and tolerance. The combination of the chromosome 4 CNV and KSR1 LOH results in a >500-fold decrease in azole susceptibility relative to the progenitor, illustrating a compelling example of rapid, yet step-wise, interplay between CNV and LOH in drug resistance evolution. The rise of drug-resistant microbes is a global health crisis. To combat this, we need to understand how these organisms evolve drug resistance. This study focuses on Candida albicans , a common fungal pathogen, and its ability to develop resistance to fluconazole, a widely used antifungal drug. We observe C . albicans rapidly evolve drug resistance through a two-step process involving large-scale genetic changes. First, it undergoes a copy number amplification, then it undergoes a loss of heterozygosity at the KSR1 gene, which is involved in sphingolipid biosynthesis. These changes work together to dramatically increase the fungus's ability to survive in the presence of the drug. This research highlights how quickly and efficiently yeast can adapt to overcome antifungal drug and emphasizes the importance of studying large-scale genetic changes, not just individual mutations, when investigating drug resistance. Our findings could help in developing new strategies to predict and prevent the emergence of resistant pathogens, ultimately improving patient care in the face of this growing threat.

Antifungal Tolerance and Resistance Emerge at Distinct Drug Concentrations and Rely upon Different Aneuploid Chromosomes

Miconazole induces aneuploidy-mediated tolerance in Candida albicans that is dependent on Hsp90 and calcineurin

Parallel evolution of fluconazole resistance and tolerance in Candida glabrata

Candida albicans exhibits heterogeneous and adaptive cytoprotective responses to antifungal compounds

Aneuploidy enables cross-tolerance to unrelated antifungal drugs in Candida parapsilosis

Aneuploidy Underlies Tolerance and Cross-Tolerance to Drugs in Candida parapsilosis

Ketoconazole induces reversible antifungal drug tolerance mediated by trisomy of chromosome R in Candida albicans

Beyond resistance: antifungal heteroresistance and antifungal tolerance in fungal pathogens

Drug resistance and tolerance in fungi

Drugs Commonly Used in Fungal Infection Risk Conditions Promote Drug Tolerance or Resistance in Candida albicans

Aneuploidy underlies paradoxical growth of rezafungin and enables cross-tolerance to echinocandins in Candida albicans

Antagonistic Changes in Sensitivity to Antifungal Drugs by Mutations of an Important ABC Transporter Gene in a Fungal Pathogen

Critical Assessment of Cell Wall Integrity Factors Contributing to in vivo Echinocandin Tolerance and Resistance in Candida glabrata

Candida albicans gains azole resistance by altering sphingolipid composition

Acquired resistance or tolerance? - in search of mechanisms underlying changes in the resistance profile of Candida albicans and Candida parapsilosis as a result of exposure to methotrexate

Step-wise evolution of azole resistance through copy number variation followed by KSR1 loss of heterozygosity in Candida albicans

Aneuploidy Mediates Rapid Adaptation to a Subinhibitory Amount of Fluconazole in Candida albicans

Emergence of Antifungal Resistant Subclades in the Global Predominant Phylogenetic Population of Candida Albicans.

Long-term stability of acquired drug resistance and resistance associated mutations in the fungal pathogen Nakaseomyces glabratus (Candida glabrata)

Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species

Role for cell density in antifungal drug resistance in Candida albicans biofilms